Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer

Ítems similars

• Factors influencing the uptake of (18)F-Fluoroestradiol (FES) in patients with estrogen receptor positive (ER+) breast cancer
  per: Peterson, Lanell M, et al.
  Publicat: (2011)
• Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: (18)F-Fluoroestradiol PET Imaging Shows Return of ER Expression
  per: Currin, Erin, et al.
  Publicat: (2016)
• Between-Patient and Within-Patient (Site-to-Site) Variability in Estrogen Receptor Binding, Measured In Vivo by (18)F-Fluoroestradiol PET
  per: Kurland, Brenda F., et al.
  Publicat: (2011)
• Fluoroestradiol (FES) Positron Emission Tomography (PET) Reveals Differences In Pharmacodynamics Of Aromatase Inhibitors, Tamoxifen, And Fulvestrant In Patients With Metastatic Breast Cancer
  per: Linden, Hannah M., et al.
  Publicat: (2011)
• A Phase 2 Study of 16α-[(18)F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)
  per: Peterson, Lanell M., et al.
  Publicat: (2013)